Sarah Boyce - 01 Feb 2023 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
President and CEO, Director
Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
01 Feb 2023
Net transactions value
-$1,155,727
Form type
4
Filing time
03 Feb 2023, 16:26:22 UTC
Previous filing
01 Feb 2023
Next filing
27 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $1,116 +900 +1.7% $1.24* 54,252 01 Feb 2023 Direct F1, F2
transaction RNA Common Stock Sale $21,844 -900 -1.7% $24.27 53,352 01 Feb 2023 Direct F1, F2, F3
transaction RNA Common Stock Options Exercise $56,890 +45,879 +86% $1.24* 99,231 02 Feb 2023 Direct F1, F2
transaction RNA Common Stock Sale $1,117,741 -45,879 -46% $24.36 53,352 02 Feb 2023 Direct F1, F2, F4
transaction RNA Common Stock Options Exercise $3,994 +3,221 +6% $1.24* 56,573 03 Feb 2023 Direct F1, F2
transaction RNA Common Stock Sale $78,141 -3,221 -5.7% $24.26 53,352 03 Feb 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -900 -0.08% $0.000000 1,146,115 01 Feb 2023 Common Stock 900 $1.24 Direct F1, F5
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -45,879 -4% $0.000000 1,100,236 02 Feb 2023 Common Stock 45,879 $1.24 Direct F1, F5
transaction RNA Stock Option (Right to Options Exercise $0 -3,221 -0.29% $0.000000 1,097,015 03 Feb 2023 Common Stock 3,221 $1.24 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 Includes restricted stock units.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.26 to $24.31.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.26 to $24.68.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter.